Mobile

A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-002894-21

A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged ≥ 65 years with overactive bladder

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to evaluate the efficacy of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d. at week 2) versus placebo with respect to the change from baseline in the number of urge urinary incontinence episodes (UUIE) per week at week 12 in patients ≥ 65 years with OAB.

Critère d'inclusion

  • Overactive bladder (OAB)

Liens